Search
Powered By HealthLine
Special Offers
Health Tools
 Cold & Flu Remedies
 Symptoms Checker
 Quiz: Cold & Flu Myths
 Flu Vaccine Guide
 Avian Flu Guide
Featured Conditions
 Cold & Flu
 Allergy
 Diet & Exercise
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Vaccine May Work Better Against Lung Disease

Different formulation seems to thwart pneumonia in high-risk group with COPD, study finds


Related Encyclopedia
 border=
Asthma
Asthma in Children
Asthma Treatment
Atelectasis
More...

Related Healthscout Videos
 border=
Viagra Saving Children
Breathing on their Own
Saving Little Lungs & Lowering Costs
Detecting Lung Disease
More...

Related Animations
 border=
Asthma
More...

Related Drug Information
 border=
Advair Diskus
Combivent
Flovent
Flovent Diskus
More...

Related News Articles
 border=
Prescription Drug Use Rising in U.S., CDC Reports
Experimental TB Test Called Fast and Accurate
Lung Damage From Secondhand Smoke Observed in Rats
Potential Cause of Asthma-Like Symptoms Spotted in Mice
More...

WEDNESDAY, Sept. 9 (HealthDay News) -- A recently developed pneumonia vaccine may be more effective in preventing infections in patients with chronic obstructive pulmonary disease (COPD) than the vaccine that is typically used, new research suggests.

Risk of pneumonia can be an ongoing problem for people with COPD, a chronic, progressive disease that causes difficulty breathing and chest tightness. The U.S. Centers for Disease Control and Prevention recommends that all adults with COPD be vaccinated against pneumonia with a vaccine referred to as PPSV23 (23-valent pneumococcal polysaccharide vaccination).

Text Continues Below



But the effectiveness of the vaccine in people with COPD hasn't been sufficiently proven, according to the study that will appear in the Sept. 15 issue of the American Journal of Respiratory and Critical Care Medicine.

"Reasonable effectiveness for this vaccine has been demonstrated in cohort studies in adults with lung disease," said study author Dr. Mark Dransfield of the University of Alabama at Birmingham, in a news release from the American Thoracic Society. "[However,] debate remains about its immunogenicity and effectiveness in COPD."

In the current study, researchers inoculated 120 adults with moderate to severe COPD with either PPSV23 or a newer vaccine, PCV7.

Several indicators showed the PCV7 vaccine produced a heightened immune response as compared to the older vaccine.

The blood of patients who had received PCV7 vaccine was also more effective at killing pneumonia-causing bacteria in six of seven serotypes, or groups of microorganisms, one month after vaccination, the researchers found.

"We have shown that PCV7 induces a superior immune response to PPSV23 in COPD at one month post-vaccination," Dransfield stated in the news release.

However, older age and prior vaccination with PPSV23 blunted the efficacy of the PCV7 vaccine, the researchers noted, and further study is needed.

More information

The National Heart, Lung, and Blood Institute has more on COPD.



--Jennifer Thomas

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 9/9/2009

Related Links
 border=
From Healthscout's partner site on allergy, MyAllergyNetwork.com
QUIZ: Test your knowledge of allergy causes and treatments
DRUGS: Common drugs used to treat allergies
SYMPTOMS: Images and information on allergy symptoms





SOURCE: American Thoracic Society, news release, Sept. 8, 2009


HealthSquare is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy